Inventiva 주식 주식분석 | 주식가격 | 뉴스 | IVA.PA | FR0013233012 | A2DLV9

날짜	Inventiva 주식 가격
	2.38 undefined
	2.45 undefined
	2.43 undefined
	2.40 undefined
	2.44 undefined
	2.41 undefined
	2.45 undefined
	2.49 undefined
	2.56 undefined
	2.52 undefined
	2.50 undefined
	2.46 undefined
	2.42 undefined
	2.45 undefined
	2.46 undefined
	2.64 undefined
	2.63 undefined
	2.50 undefined
	2.20 undefined
	2.24 undefined
	2.31 undefined
	2.53 undefined

날짜	Inventiva 매출	Inventiva EBIT	Inventiva 이익
2029e	428.36 백만 undefined	0 undefined	11.52 백만 undefined
2028e	248.49 백만 undefined	37.87 백만 undefined	-18.61 백만 undefined
2027e	68.88 백만 undefined	-84.78 백만 undefined	-82.4 백만 undefined
2026e	39.14 백만 undefined	-119.32 백만 undefined	-125.6 백만 undefined
2025e	25.6 백만 undefined	-107.33 백만 undefined	-131.02 백만 undefined
2024e	5.54 백만 undefined	-118.09 백만 undefined	-171.16 백만 undefined
2023	17.48 백만 undefined	-102.67 백만 undefined	-110.43 백만 undefined
2022	12.18 백만 undefined	-56.86 백만 undefined	-54.27 백만 undefined
2021	4.19 백만 undefined	-51.16 백만 undefined	-49.64 백만 undefined
2020	372,000 undefined	-29.7 백만 undefined	-33.62 백만 undefined
2019	7 백만 undefined	-30.31 백만 undefined	-30.22 백만 undefined
2018	3.2 백만 undefined	-29.86 백만 undefined	-33.62 백만 undefined
2017	4.8 백만 undefined	-22.19 백만 undefined	-19.08 백만 undefined
2016	9.45 백만 undefined	-12.05 백만 undefined	-7.05 백만 undefined
2015	4.88 백만 undefined	-14.88 백만 undefined	-8.82 백만 undefined
2014	3.28 백만 undefined	-13.47 백만 undefined	-7.49 백만 undefined
2013	3.07 백만 undefined	-12.47 백만 undefined	-7.14 백만 undefined

	매출	EBIT	이익
2013	3.07 백만 EUR	-12.47 백만 EUR	-7.14 백만 EUR
2014	3.28 백만 EUR	-13.47 백만 EUR	-7.49 백만 EUR
2015	4.88 백만 EUR	-14.88 백만 EUR	-8.82 백만 EUR
2016	9.45 백만 EUR	-12.05 백만 EUR	-7.05 백만 EUR
2017	4.8 백만 EUR	-22.19 백만 EUR	-19.08 백만 EUR
2018	3.2 백만 EUR	-29.86 백만 EUR	-33.62 백만 EUR
2019	7 백만 EUR	-30.31 백만 EUR	-30.22 백만 EUR
2020	372,000 EUR	-29.7 백만 EUR	-33.62 백만 EUR
2021	4.19 백만 EUR	-51.16 백만 EUR	-49.64 백만 EUR
2022	12.18 백만 EUR	-56.86 백만 EUR	-54.27 백만 EUR
2023	17.48 백만 EUR	-102.67 백만 EUR	-110.43 백만 EUR
2024e	5.54 백만 EUR	-118.09 백만 EUR	-171.16 백만 EUR
2025e	25.6 백만 EUR	-107.33 백만 EUR	-131.02 백만 EUR
2026e	39.14 백만 EUR	-119.32 백만 EUR	-125.6 백만 EUR
2027e	68.88 백만 EUR	-84.78 백만 EUR	-82.4 백만 EUR
2028e	248.49 백만 EUR	37.87 백만 EUR	-18.61 백만 EUR
2029e	428.36 백만 EUR	0 EUR	11.52 백만 EUR

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
3	3	4	9	4	3	6	0	4	12	17	5	25	39	68	248	428
-	-	33.33	125.00	-55.56	-25.00	100.00	-	-	200.00	41.67	-70.59	400.00	56.00	74.36	264.71	72.58
-	-	-	-	-	-	-	-	175.00	141.67	-	-	-	-	-	-	-
0	0	0	0	0	0	0	4	7	17	0	0	0	0	0	0	0
-12	-13	-14	-12	-22	-29	-30	-29	-51	-56	-102	-118	-107	-119	-84	37	0
-400.00	-433.33	-350.00	-133.33	-550.00	-966.67	-500.00	-	-1,275.00	-466.67	-600.00	-2,360.00	-428.00	-305.13	-123.53	14.92	-
-7	-7	-8	-7	-19	-33	-30	-33	-49	-54	-110	-171	-131	-125	-82	-18	11
-	-	14.29	-12.50	171.43	73.68	-9.09	10.00	48.48	10.20	103.70	55.45	-23.39	-4.58	-34.40	-78.05	-161.11
10.03	10.03	10.03	10.03	15.52	20.54	23.52	33.87	39.17	41.45	45.35	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

13.52	17.14	22.6	24.87	59.05	56.69	35.84	105.69	86.55	86.74	26.92
0.84	0.83	0.91	0.77	0.06	0.01	0	0.05	4	0	3.81
1.31	3.06	3.78	7.37	6.8	13.34	12.15	23.63	17.18	10.67	12.39
530	477	480	471.88	473	410	387	320	392	373	417
0	0	0.85	7.76	0.84	1.18	0.5	3.31	7.45	8.6	4.66
16.2	21.51	28.62	41.25	67.22	71.63	48.88	133	115.58	106.38	48.19
6.03	5.91	5.57	4.96	4.52	4.26	3.72	3.28	3.2	7.39	9.13
0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	13.47	7.59	9.34	0
2	2.21	2.38	2.07	1.81	1.54	1.23	0.94	0.77	0.57	0.54
0	0	0	0	0	0	0	0	0	0	0
62.89	43.51	24.01	0.58	0.83	2.37	3.14	1.71	2.44	1.67	11.71
70.92	51.63	31.96	7.61	7.15	8.18	8.09	19.39	14	18.96	21.37
87.12	73.13	60.58	48.86	74.37	79.81	56.96	152.39	129.58	125.34	69.56

0	0	0	0	164	223	268	386	409	421	521
0	0	0	0	44.99	77.46	86.01	139.67	165.07	173.89	201.86
0	0	0	0	16.74	-16.09	-44.89	-28.84	-76.61	-128.83	-234.41
59.01	0	42.77	35.72	0	0	0	-0	-0	0	-0
0	0	0	0	0	0	0	0	0	0	0
59.01	0	42.77	35.72	61.89	61.6	41.39	111.21	88.87	45.48	-32.03
1.68	1.89	3.61	4.36	5.38	8.37	7.49	6.92	14.6	19.36	37.68
0	0	2.18	2.17	2.08	2.32	2.34	2.89	2.93	3.35	3.57
3.88	3.6	1.76	1.92	1.41	4.25	3.95	4.08	4.04	2.25	3.68
0	0	10.25	0	0	0	0	0	0	0	0
0.06	0.06	0.19	0.14	0.14	0.15	0.08	0.02	1.28	5.75	5.23
5.62	5.54	7.75	8.6	9.01	15.08	13.87	13.91	22.85	30.7	50.16
0.1	0.05	0.5	0.36	0.22	0.07	0	10.04	8.84	28.66	32.18
22.16	15.71	9.09	3.01	0	0	0	0	0	0	0
0.23	0.34	0.47	1.16	3.24	3.06	1.7	3.76	1.43	11.16	19.25
22.49	16.09	10.06	4.54	3.46	3.13	1.7	13.8	10.27	39.83	51.44
28.11	21.63	17.81	13.14	12.47	18.22	15.57	27.71	33.12	70.53	101.59
87.12	21.63	60.58	48.86	74.37	79.81	56.96	138.92	121.98	116	69.56

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
0	0	-8	-7	-19	-33	-30	-33	-49	-54
0	0	1	1	1	2	1	1	0	1
0	0	0	0	0	0	0	0	4	-1
-16	-14	3	0	4	-3	0	-2	6	4
0	0	-9	-9	-3	0	0	3	-4	3
0	0	0	0	0	0	0	0	0	0
0	0	-1	-3	-3	0	-3	-8	-7	-3
-16	-14	-13	-14	-17	-34	-28	-30	-47	-44
0	0	0	0	0	0	0	0	0	0
18	18	18	17	6	0	0	-8	-1	8
18	18	19	17	6	0	0	-8	-1	9
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	9	0	28
0	0	0	0	45	32	8	101	25	8
0	0	0	0	45	32	8	111	25	37
-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0
2	3	5	2	34	-2	-20	69	-19	0
-16.01	-14.79	-14.95	-15.09	-17.43	-34.76	-28.54	-30.88	-48.16	-45.49
0	0	0	0	0	0	0	0	0	0

Inventiva 브루토마진	Inventiva 이익 마진	Inventiva EBIT-마진	Inventiva 이익 마진
2029e	146.28 %	0 %	2.69 %
2028e	146.28 %	15.24 %	-7.49 %
2027e	146.28 %	-123.09 %	-119.63 %
2026e	146.28 %	-304.85 %	-320.89 %
2025e	146.28 %	-419.26 %	-511.76 %
2024e	146.28 %	-2,130.1 %	-3,087.28 %
2023	146.28 %	-587.43 %	-631.84 %
2022	146.28 %	-466.84 %	-445.64 %
2021	178.35 %	-1,219.89 %	-1,183.48 %
2020	1,186.56 %	-7,983.87 %	-9,037.37 %
2019	146.28 %	-433.15 %	-431.81 %
2018	146.28 %	-933.94 %	-1,051.52 %
2017	146.28 %	-462.58 %	-397.81 %
2016	146.28 %	-127.56 %	-74.59 %
2015	146.28 %	-305.13 %	-180.98 %
2014	146.28 %	-410.2 %	-228.27 %
2013	146.28 %	-406.19 %	-232.57 %

	브루토마진	EBIT-마진	이익 마진
2013	146.28 %	-406.19 %	-232.57 %
2014	146.28 %	-410.2 %	-228.27 %
2015	146.28 %	-305.13 %	-180.98 %
2016	146.28 %	-127.56 %	-74.59 %
2017	146.28 %	-462.58 %	-397.81 %
2018	146.28 %	-933.94 %	-1,051.52 %
2019	146.28 %	-433.15 %	-431.81 %
2020	1,186.56 %	-7,983.87 %	-9,037.37 %
2021	178.35 %	-1,219.89 %	-1,183.48 %
2022	146.28 %	-466.84 %	-445.64 %
2023	146.28 %	-587.43 %	-631.84 %
2024e	146.28 %	-2,130.1 %	-3,087.28 %
2025e	146.28 %	-419.26 %	-511.76 %
2026e	146.28 %	-304.85 %	-320.89 %
2027e	146.28 %	-123.09 %	-119.63 %
2028e	146.28 %	15.24 %	-7.49 %
2029e	146.28 %	0 %	2.69 %

날짜	Inventiva 주당 매출	Inventiva EBIT 당 주식	Inventiva 주당 이익
2029e	4.93 undefined	0 undefined	0.13 undefined
2028e	2.86 undefined	0 undefined	-0.21 undefined
2027e	0.79 undefined	0 undefined	-0.95 undefined
2026e	0.45 undefined	0 undefined	-1.45 undefined
2025e	0.29 undefined	0 undefined	-1.51 undefined
2024e	0.06 undefined	0 undefined	-1.97 undefined
2023	0.39 undefined	-2.26 undefined	-2.43 undefined
2022	0.29 undefined	-1.37 undefined	-1.31 undefined
2021	0.11 undefined	-1.31 undefined	-1.27 undefined
2020	0.01 undefined	-0.88 undefined	-0.99 undefined
2019	0.3 undefined	-1.29 undefined	-1.28 undefined
2018	0.16 undefined	-1.45 undefined	-1.64 undefined
2017	0.31 undefined	-1.43 undefined	-1.23 undefined
2016	0.94 undefined	-1.2 undefined	-0.7 undefined
2015	0.49 undefined	-1.48 undefined	-0.88 undefined
2014	0.33 undefined	-1.34 undefined	-0.75 undefined
2013	0.31 undefined	-1.24 undefined	-0.71 undefined

	주당 매출	EBIT 당 주식	주당 이익
2013	0.31 EUR	-1.24 EUR	-0.71 EUR
2014	0.33 EUR	-1.34 EUR	-0.75 EUR
2015	0.49 EUR	-1.48 EUR	-0.88 EUR
2016	0.94 EUR	-1.2 EUR	-0.7 EUR
2017	0.31 EUR	-1.43 EUR	-1.23 EUR
2018	0.16 EUR	-1.45 EUR	-1.64 EUR
2019	0.3 EUR	-1.29 EUR	-1.28 EUR
2020	0.01 EUR	-0.88 EUR	-0.99 EUR
2021	0.11 EUR	-1.31 EUR	-1.27 EUR
2022	0.29 EUR	-1.37 EUR	-1.31 EUR
2023	0.39 EUR	-2.26 EUR	-2.43 EUR
2024e	0.06 EUR	0 EUR	-1.97 EUR
2025e	0.29 EUR	0 EUR	-1.51 EUR
2026e	0.45 EUR	0 EUR	-1.45 EUR
2027e	0.79 EUR	0 EUR	-0.95 EUR
2028e	2.86 EUR	0 EUR	-0.21 EUR
2029e	4.93 EUR	0 EUR	0.13 EUR

	주식 수량
2013	10.03 백만 Aktien
2014	10.03 백만 Aktien
2015	10.03 백만 Aktien
2016	10.03 백만 Aktien
2017	15.52 백만 Aktien
2018	20.54 백만 Aktien
2019	23.52 백만 Aktien
2020	33.87 백만 Aktien
2021	39.17 백만 Aktien
2022	41.45 백만 Aktien
2023	45.35 백만 Aktien
2024e	45.35 백만 Aktien
2025e	45.35 백만 Aktien
2026e	45.35 백만 Aktien
2027e	45.35 백만 Aktien
2028e	45.35 백만 Aktien
2029e	45.35 백만 Aktien

%-지분	이름	주식	변경
9.04396 %	BVF Partners L.P.	7,859,459	0
9.01683 %	New Enterprise Associates (NEA)	7,835,884	2,262,931
8.26531 %	The Invus Group, LLC	7,182,792	7,182,792
6.45804 %	Cren (Frederic)	5,612,224	0
5.93448 %	Qatar Investment Authority	5,157,233	0
5.83440 %	Sofinnova Partners	5,070,266	0
5.76347 %	Andera Partners S.A.S.	5,008,620	5,008,620
5.20795 %	Perceptive Advisors LLC	4,525,862	4,525,862
4.46763 %	Broqua (Pierre)	3,882,500	0
4.42526 %	Yiheng Capital Management, L.P.	3,845,676	1,489,176
1.53980 %	Inventiva SA Employees	1,338,127	363,000
0.13528 %	Amundi Asset Management, SAS	117,564	0
0.01685 %	BG Fund Management Luxembourg S.A.	14,640	-15,142
0.00861 %	Crossinvest SA	7,486	0
0 %	DNCA Investments	0	-393,548
0 %	Financi¿re Arbevel	0	-21,000
0 %	Apo Asset Management GmbH	0	-9,252
0 %	Polar Capital LLP	0	-1,000,000
0 %	Medical Strategy GmbH	0	-80,356
0 %	Candriam Luxembourg S.A.	0	-104,612

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
AbbVie	공급업체고객	-0,22	0,41	-0,29	-0,85	-0,72	-0,27

What values and corporate philosophy does Inventiva represent?

Inventiva SA represents values of innovation, research, and commitment to improving patients' lives. With a strong corporate philosophy, the company focuses on developing breakthrough therapies for the treatment of fibrotic diseases, oncology, and NASH. Inventiva SA's dedication to scientific excellence and collaborative partnerships drives its mission to address unmet medical needs and provide effective therapeutic solutions. Through its innovative approach and commitment to patient health, Inventiva SA has positioned itself as a leading player in the pharmaceutical industry.

In which countries and regions is Inventiva primarily present?

Inventiva SA is primarily present in France and Switzerland.

What significant milestones has the company Inventiva achieved?

Inventiva SA, a leading company in the stock market, has accomplished several significant milestones. One of its notable achievements includes the successful completion of Phase 2b clinical trials for its drug candidate, lanifibranor. Additionally, Inventiva SA has successfully secured partnerships and collaborations with various pharmaceutical companies to further advance its innovative research and development. The company's commitment to building a strong and diverse portfolio has also resulted in obtaining key patents and regulatory approvals for its ground-breaking therapies. These remarkable achievements highlight Inventiva SA's dedication to revolutionizing the healthcare industry and position the company as a promising investment opportunity.

What is the history and background of the company Inventiva?

Inventiva SA is a pharmaceutical company founded in 2011 in France. The company specializes in the development and commercialization of innovative therapies for the treatment of diseases with high unmet medical needs. With a strong expertise in drug discovery and medicinal chemistry, Inventiva aims to address significant therapeutic challenges through its proprietary technology platforms. The company has a diverse portfolio of drug candidates targeting a range of conditions, including fibrosis, oncology, and rare genetic diseases. Inventiva has established collaborations with various research and academic institutions to support its research efforts. With a dedicated team and promising pipeline, Inventiva SA is poised to make a significant contribution to the healthcare industry.

Who are the main competitors of Inventiva in the market?

The main competitors of Inventiva SA in the market include other companies operating in the biopharmaceutical industry, such as Novartis, Amgen, Gilead Sciences, and Pfizer. These companies also focus on research, development, and commercialization of innovative therapies for various diseases.

In which industries is Inventiva primarily active?

Inventiva SA is primarily active in the biopharmaceutical industry.

What is the business model of Inventiva?

The business model of Inventiva SA focuses on the development and commercialization of innovative therapies for the treatment of various diseases. As a biopharmaceutical company, Inventiva SA aims to discover and develop small molecule drugs that target various nuclear receptors involved in the regulation of gene expression. By leveraging its expertise in nuclear receptors, Inventiva SA aims to bring novel therapies to market that can address unmet medical needs. With a strong pipeline of drug candidates in various stages of development, Inventiva SA is dedicated to improving patients' lives and creating value for its shareholders through the research and development of innovative therapies.

Inventiva 2024의 P/E 비율은 얼마입니까?

Inventiva의 P/E 비율은 -0.63입니다.

Inventiva 2024의 KUV는 얼마입니까?

Inventiva의 P/S 비율은 19.43입니다.

Inventiva의 AlleAktien 품질 점수는 얼마인가요?

Inventiva에 대한 AlleAktien 품질 점수는 7/10입니다.

Inventiva 2024의 매출은 얼마인가요?

예상되는 Inventiva 매출은 5.54 백만 EUR입니다.

Inventiva 2024의 이익은 얼마인가요?

예상되는 Inventiva 이익은 -171.16 백만 EUR입니다.

Inventiva은 무엇을 하나요?

The company Inventiva SA is a company specializing in the development of therapies for serious diseases. The company is based in France and also has branches in Germany and the USA. The various divisions of Inventiva SA include drug development and clinical research, as well as the manufacturing of diagnostics and medications. The company specializes in the development of medications for serious diseases such as rare genetic disorders or fibrosis. It takes an interdisciplinary approach and works closely with research institutions and biopharmaceutical companies. One of Inventiva SA's key products is the medication Lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a liver disease caused by obesity and diabetes, which can lead to cirrhosis and liver cancer. Lanifibranor is intended to improve liver health and reduce inflammation by influencing various signaling pathways in the body. The medication is currently in clinical development and has already shown promising results in clinical trials. Another product of Inventiva SA is the diagnostic test called Odiparcil, which supports the treatment of mucopolysaccharidosis (MPS). MPS is a rare genetic disease that can cause debilitating symptoms such as bone pain, shortness of breath, and changes in facial features. The Odiparcil test allows for the diagnosis of MPS and helps doctors choose the right therapy for their patients. Inventiva SA mainly finances its research and development projects through partnerships and licensing agreements with major pharmaceutical companies. For example, the company has a partnership with AbbVie, a global leader in biopharmaceuticals, to advance the development of Lanifibranor. Additionally, the company has significant investments from public and private investors as well as foundations. Overall, Inventiva SA takes a strategic and scientific approach to develop medications and diagnostics for serious diseases with unmet medical needs. The company has a strong pipeline of products in development and a promising partnership with a global biopharmaceutical manufacturer. With its focus on developing innovative therapies for complex diseases, Inventiva SA can contribute to improving the lives of millions of patients worldwide.

Inventiva 배당금은 얼마입니까?

Inventiva은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Inventiva이 얼마나 자주 배당을 지급하나요?

Inventiva의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Inventiva ISIN이 무엇입니까?

Inventiva의 ISIN은 FR0013233012입니다.

Inventiva WKN은 무엇인가요?

Inventiva의 WKN은 A2DLV9입니다.

Inventiva 티커는 무엇인가요?

Inventiva의 티커는 IVA.PA입니다.

Inventiva이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Inventiva은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Inventiva은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Inventiva의 배당 수익률은 얼마입니까?

Inventiva의 현재 배당 수익률은 입니다.

Inventiva의 배당금은 언제 지급되나요?

Inventiva은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Inventiva의 배당금은 얼마나 안전한가요?

Inventiva은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Inventiva의 배당금은 얼마입니까?

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Inventiva이(가) 속해 있는 섹터는 어디인가요?

Inventiva은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Inventiva kaufen, um die vorherige Dividende zu erhalten?

Inventiva의 마지막 배당금을 0 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Inventiva의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Inventiva의 2023년도 배당금은 얼마였습니까?

2023년에 Inventiva는 0 EUR를 배당금으로 지급했습니다.

Inventiva는 어떤 화폐로 배당금을 지급하나요?

Inventiva의 배당금은 EUR에 지급됩니다.

증권거래소	Inventiva 티커
뒤셀도르프	6IV.DU
EURONEXT	IVA.PA
프랑크푸르트	6IV.F
LONDON	0RNK.L
LONDON STOCK EXCHANGE	0RNK.L
뮌헨	6IV.MU
파리	IVA.PA
PNK	IVEVF

Inventiva 티커	Inventiva FIGI
IVA:FP	BBG00DGY8YM2
6IV:GR	BBG00G25Q7T5
6IV:GF	BBG00G25Q7V2
6IV:GD	BBG00G25Q7W1
6IV:GS	BBG00G25Q7Y9
6IV:GM	BBG00G25Q7Z8
6IV:GB	BBG00G25Q804
IVAEUR:EO	BBG00G2CJ9L2
IVAEUR:XH	BBG00G2CJ9P8
IVAEUR:XF	BBG00G2CJ9R6
IVAEUR:XE	BBG00G2CJ9T4
IVAEUR:XJ	BBG00G2CJ9V1
IVAEUR:XL	BBG00G2CJ9W0
IVAEUR:XG	BBG00G2CJ9X9
IVAEUR:XO	BBG00G2CJ9Y8
IVAEUR:XS	BBG00G2CJB28
IVAEUR:XA	BBG00G2CJB37
IVAEUR:E1	BBG00G2CJB46
IVAEUR:XT	BBG00G2CJB55
IVAEUR:XW	BBG00G2CJB64
IVAEUR:XU	BBG00G2CJB73
IVAEUR:XV	BBG00G2CJB82
IVAEUR:EU	BBG00G2CJBB8
IVAP:B3	BBG00G5KZHC5
IVAP:L3	BBG00G5KZHT7
IVAP:PO	BBG00G5KZKD7
IVAEUR:XM	BBG00J9WSQP3
0RNK:LN	BBG00JHW7WB9
IVAEUR:XX	BBG00JN8LDC0
6IV:GZ	BBG00NGB2J12
IVEVF:US	BBG00NW3RHK8
IVEVF:PQ	BBG00NW3RHZ2
IVEVF:UV	BBG00NW3RJ06
IVAEUR:X2	BBG00Q6S7T67
IVAP:IX	BBG00XX7F3C9
IVAP:EB	BBG00XX7FQQ3
IVAP:I2	BBG00XX7FQY4
IVAP:L1	BBG00Y91T369
6IV:TH	BBG00YZ3YP07
6IV:QT	BBG00Z179HM4
IVAGBP:XS	BBG00Z6PQYG0
IVAGBP:XH	BBG00Z6PQYK5
IVAGBP:XF	BBG00Z6PQYM3
IVAGBP:XE	BBG00Z6PQYP0
IVAGBP:XL	BBG00Z6PQYR8
IVAGBP:XG	BBG00Z6PQYS7
IVAGBP:XO	BBG00Z6PQYT6
IVAGBP:XA	BBG00Z6PQYY0
IVAGBP:XT	BBG00Z6PQZ04
IVAGBP:XW	BBG00Z6PQZ13
IVAGBP:XU	BBG00Z6PQZ22
IVAGBP:XV	BBG00Z6PQZ40
IVAGBP:XM	BBG00Z6PQZ59
IVAGBP:EU	BBG00Z6PQZD0
IVAP:S1	BBG013N7M8W4
IVAP:S4	BBG013N86M86
6IV:LA	BBG018H9HCR9
6IV:LU	BBG018J34DH3
IVA1USD:EO	BBG01F7JXYY8
IVA1USD:X2	BBG01F7JXYZ7
IVA1USD:XH	BBG01F7JXZ11
IVA1USD:XF	BBG01F7JXZ39
IVA1USD:XE	BBG01F7JXZ57
IVA1USD:XJ	BBG01F7JXZ66
IVA1USD:XL	BBG01F7JXZ75
IVA1USD:XG	BBG01F7JXZ84
IVA1USD:XO	BBG01F7JXZ93
IVA1USD:XA	BBG01F7JXZF6
IVA1USD:E1	BBG01F7JXZG5
IVA1USD:XT	BBG01F7JXZH4
IVA1USD:XW	BBG01F7JXZJ2
IVA1USD:XU	BBG01F7JXZK0
IVA1USD:XY	BBG01F7JXZL9
IVA1USD:XV	BBG01F7JXZM8
IVA1USD:XM	BBG01F7JXZN7
IVA1USD:XQ	BBG01F7JXZP5
IVA1USD:XX	BBG01F7JXZQ4
IVA1USD:XZ	BBG01F7JXZR3
IVA1USD:X1	BBG01F7JXZT1
IVA1USD:EU	BBG01F7JXZW7
IVAP:QX	BBG01GN960K9
IVAP:QE	BBG01GN962V3

한 눈에 저평가된 주식을 인식하세요

Inventiva 주식 주식과 주식 분석 Inventiva ariva, Inventiva onvista, Inventiva finanzen.net, Inventiva aktienfinder, Inventiva marketscreener, Inventiva marketwatch, Inventiva bloomberg, Inventiva handelsblatt, Inventiva wiwo, Inventiva forum

가격

가격

티커IVA.PA

ISINFR0013233012

WKNA2DLV9

Inventiva 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Inventiva 주가 이력

Inventiva 주식 매출, EBIT, 이익 FR0013233012 · A2DLV9

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Inventiva 매출, 이익 및 EBIT 역사

Inventiva 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Inventiva 주식 마진 FR0013233012 · A2DLV9

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Inventiva 마진 역사

Inventiva 주식 매출, EBIT, 주당 순이익 FR0013233012 · A2DLV9

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Inventiva 매출, 이익 및 EBIT 주당 역사

Inventiva 주식 및 주식 분석

Inventiva Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Inventiva 역사적인 P/E, EBIT 및 P/S에 따른 평가

Inventiva 주식 수량 FR0013233012 · A2DLV9

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

Inventiva 수익 예상

Inventiva 수익 놀라움

Inventiva 주식 주주 구조

Inventiva 임원진 및 경영진

Inventiva 공급망

Inventiva 주식에 대한 자주 묻는 질문

What values and corporate philosophy does Inventiva represent?

In which countries and regions is Inventiva primarily present?

What significant milestones has the company Inventiva achieved?

What is the history and background of the company Inventiva?

Who are the main competitors of Inventiva in the market?

Inventiva 주식
주식과 주식 분석 Inventiva ariva, Inventiva onvista, Inventiva finanzen.net, Inventiva aktienfinder, Inventiva marketscreener, Inventiva marketwatch, Inventiva bloomberg, Inventiva handelsblatt, Inventiva wiwo, Inventiva forum

티커
IVA.PA

ISIN
FR0013233012

WKN
A2DLV9